BioSpace News Archive

Ascendis Pharma A/S (Nasdaq: ASND) today announced that the Company will hold a conference call and live webcast on Wednesday, March 2, 2022 at 4:30 p.m. Eastern Time (ET) to review its 2021 financial results and provide a business update.

Sunshine Biopharma Inc. (NASDAQ: “SBFM” and SBFMW) (the “Company” or “Sunshine Biopharma”), a pharmaceutical company focused on the research, development and commercialization of oncology and antiviral drugs today announced that it has entered into an agreement with the University of Arizona for the purposes of advancing the development of novel PLpro inhibitors discovered by University of Arizona and University of Illinois Chicago researchers

PharmAbcine Inc. (KOSDAQ: 208340ks), a clinical-stage biotech company focusing on the development of next-generation antibody therapeutics, announced today the completion of last patient last visit in its Phase Ib combination trial for mTNBC (metastatic Triple-Negative Breast Cancer) patients in Australia.

AIkido Pharma Inc., announced that it has entered into a securities purchase agreement with certain institutional investors to purchase 11,000 shares of Series O redeemable convertible preferred stock and 11,000 shares of Series P redeemable convertible preferred stock.

Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) (“Amylyx” or the “Company”), today announced that its Marketing Authorisation Application (MAA) to the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) for AMX0035 (sodium phenylbutyrate [PB] and ursodoxicoltaurine [TURSO; also known as taurursodiol]) for the treatment of amyotrophic lateral sclerosis (ALS) has been validated and is now under CHMP review.

Science Applications International Corp. has partnered with Yale School of Nursing to fund research and provide recommendations to improve access to resources such as vaccines during a national response to a crisis.

Clovis Oncology, Inc. (NASDAQ: CLVS) today announced a Trial-in-Progress poster detailing the Phase 1 portion of the LuMIERE clinical study for its targeted radiotherapy candidate FAP-2286 and a presentation titled “Initial Experience with FAP-2286 Imaging” related to an ongoing investigator-initiated trial (IIT) evaluating the ability of imaging agent gallium-68 (68Ga)-FAP-2286 to detect metastatic cancer in patients with solid tumors.

Octave, the developer of a fully-integrated Precision Care Solution built to deliver comprehensive insights that bring scientific clarity to multiple sclerosis (MS), today announced the presentation of data based on eight posters at the ACTRIMS Forum 2022.

enVVeno Medical Corporation announced that positive thirty-month VenoValve first-in-human data was presented at the 34th Annual Meeting of the American Venous Forum being held February 23-26, 2022 in Orlando, Florida.

9 Meters Biopharma, Inc., a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases, announced the publication of encouraging data in the journal Critical Care Explorations, accessible online here, on the use of larazotide to treat pediatric patients with multisystem inflammatory syndrome in children resulting from COVID-19.